Full-Time
Cell and gene therapy CDMO services
No salary listed
Watertown, MA, USA
In Person
Bachelor's
See people who can refer or advise you
Landmark Bio is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. It provides end-to-end services including drug development consulting, process analytical development, cGMP manufacturing, and CMC regulatory consulting to turn research into clinical programs. Its offerings are tailored services rather than products, delivered through collaborations with academia, physicians, biopharma, and research hospitals to address manufacturing costs and complexities. Its goal is to help programs reach clinical trials and commercial use faster while meeting regulatory standards and budget constraints, increasing patient access to advanced therapies.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Watertown, Massachusetts
Founded
N/A
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Unlimited Paid Time Off
Flexible Work Hours
Hybrid Work Options
Professional Development Budget
Conference Attendance Budget
Wellness Program
Mental Health Support
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Phone/Internet Stipend
Home Office Stipend
Landmark Bio has secured up to $18.3 million in funding from ARPA-H through its TRANSFORM-EV programme, with support from national advisory firm EverGlade. The three-year award will fund development of a continuous manufacturing platform for extracellular vesicles, potentially benefiting advanced therapies including viral vectors and cell therapies. The project aims to overcome current low-yield, high-cost batch manufacturing methods by integrating advanced upstream, downstream and analytical technologies. EverGlade supported Landmark Bio through negotiations, including multiple redesigns of work statements, milestones and financial documentation. EverGlade specialises in helping innovators navigate federal funding from agencies including ARPA-H, BARDA and DARPA. Landmark Bio, an Artis BioSolutions company, operates from Watertown, Massachusetts, providing process development and GMP manufacturing for advanced therapies.
Artis BioSolutions has appointed Dr Kate Broderick as Chief Scientific Innovation Officer, effective 9 February 2026. She will lead scientific strategy and innovation initiatives across the company's platform for developing and manufacturing genetic medicines. Dr Broderick brings over 25 years of experience in nucleic acid medicine and DNA- and RNA-based vaccine development. Most recently, she served as Chief Innovation Officer at Maravai LifeSciences. Previously, at Inovio Pharmaceuticals, she led R&D teams that advanced multiple clinical-stage programmes, including a DNA-based COVID-19 vaccine through Phase 3 testing, and secured over $100 million in non-dilutive funding. The appointment comes as Artis prepares to close its acquisition of Syngoi Technologies, expected in the first quarter of 2026. Dr Broderick holds a PhD in Molecular Genetics from the University of Glasgow.
Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, today announced its launch, alongside its...